Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

Video

In Partnership With:

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Ami Vijay Desai, MD, assistant professor of pediatrics, University of Chicago Comer Children’s Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors. She presented these findings at the 2018 ASCO Annual Meeting.

The trial followed a 3+3 dose escalation format and investigated 4 dose levels, Desai says. Researchers were able to escalate to the fourth dose level—at the third level, there was 1 dose-limiting toxicity of increased creatinine for >7 days. At the fourth level, there were 3 dose-limiting toxicities across 2 patients. Desai says these toxicities were reversible on discontinuation of drug.

Phase I data suggest the recommended dose level of entrectinib for pediatric patients is 550 mg/m2, according to Desai.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,